Table 1.
HER2-targeted TKI response in HER-altered cancer cell lines. Comparison of the IC50 values for neratinib, lapatinib, and tucatinib in the 22 EGFR-mutant, EGFR-amplified, HER2-mutant, HER2-mutant, and HER3-mutant cancer cell lines.
 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.